enGene Therapeutics Inc. (ENGN) › Operating Cash FlowenGene Therapeutics Inc. (ENGN) — Operating Cash FlowAnnual figures by period end, from SEC filings.2022-10-31: -$17.59M2023-10-31: -$24.74M2024-10-31: -$48.28M2025-10-31: -$99.24M-$99.24M2022-10-31Operating Cash Flow (USD)2025-10-31Period endedOperating Cash FlowChange YoYSource filing2025-10-31-$99.24M—2025-12-22From 2024-11-012024-10-31-$48.28M—2025-12-22From 2023-11-012023-10-31-$24.74M—2024-12-19From 2022-11-012022-10-31-$17.59M—2024-01-29From 2021-11-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)